Checking In, in Deep Summer, 2025

SWOG authors: New NIH public access requirements are now in effect
NIH Public Access Policy has long required that accepted manuscripts on NIH-funded work be submitted to PubMed Central. For manuscripts accepted for publication after July 1, 2025, the timeline for that submission has been considerably condensed.

The updated policy now requires that the “Author Accepted Manuscript” be submitted to PubMed Central upon acceptance, and PubMed Central will make it publicly available upon the “Official Date of Publication” (a 12-month embargo period is no longer allowed).

This policy applies only to publications of research funded by NIH grants, and failure to adhere to the policy could threaten our access to continued NIH funding.  

We are working on the precise operationalization of this new edict, but in the meantime, please be sure to include the SWOG publications office (pubs@swog.org) in planning a SWOG manuscript submission, and reach out if you have questions.

The updated NIH policy online includes definitions of the terms in quotes above.

Workbenches: Now all lined up on swog.org
If you use swog.org regularly, you may notice a new item in the top menu bar-to help SWOG members find tools and resources more quickly, we have consolidated the site's role-based "workbenches" into a single new drop-down menu. Workbenches are curated sets of helpful tools and resources, usually specific to a member role or member type. The ORP/CRA Workbench, Study Chair Workbench, VA Workbench, and more – previously spread across multiple menus – are all now accessible by clicking on “Workbenches.”

Hope’s Next Generation Fund accepting proposals until August 1st
Most Hope Foundation grant programs directly fund research. The Next Generation Fund, by contrast, is more of an open call to SWOG members, collaborators, and staff to submit proposals for projects and programs that will broadly advance the group’s work. Examples of programs born from Next Generation Fund support include our VA Storefront Award program, a palliative care symposium that blossomed into our palliative care committee, and Hope’s CRA/Nurse Travel Support Program, which has to this point funded the travel of 113 oncology research professionals to SWOG group meetings, plus more awards for travel to Chicago this fall. Hope’s open call for novel project ideas has crowdsourced dozens of new SWOG and Hope initiatives over the years. The program is accepting new proposals until August 1st.

 Stay tuned next Friday for the regular, full-length column.

___________________________________________________

Trial of the Week

S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer 
(Lung-MAP Non-Matched Sub-Study) 

With the recent activation of non-match sub-study S1800E, our Lung-MAP umbrella trial in non-small cell lung cancer returns to prior glory. 

As a non-match sub-study, S1800E serves as a treatment option for Lung-MAP patients whose genomic screening does not identify an alteration that would pair them with one of Lung-MAP’s biomarker sub-studies. 

S1800E is enrolling patients whose stage IV or recurrent NSCLC has acquired resistance to platinum-based chemotherapy and immunotherapy. The study randomizes these patients to treatment with a standard of care combination of docetaxel and ramucirumab, plus or minus the anti-PD1 drug cemiplimab.

The study team hypothesizes that adding anti-PD1 therapy to second- or third-line treatment may reverse resistance to immunotherapy in these patients and improve overall survival. 

Remember that with its latest revision, Lung-MAP 3.0 now accepts past test results from a wide range of next-generation sequencing platforms for initial patient screening and sub-study assignment, without the need for patients to provide new tumor or blood samples.

Non-match sub-study S1800E is a potential FDA drug registration trial. 

Drs. Saiama Waqar (also vice-chair of Lung-MAP overall) and Tianhong Lee are S1800E sub-study chairs, and the trial’s enrollment goal is 378 participants. It’s currently open at almost 200 sites, with roughly twice that number still in the process of activating it. 

Is your site on that list? 

Learn more via the SWOG S1800E page or the CTSU S1800E page. A patient-friendly summary is also available, at swog.org/S1800E, which you can use when presenting the trial to a patient (soon to be available in Spanish as well).